Publicacións nas que colabora con Antonio Llombart Cussac (13)

2021

  1. Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial

    The Lancet Oncology, Vol. 22, Núm. 6, pp. 858-871

  2. Pembrolizumab plus eribulin in hormone-receptor–positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase Ⅱ trial

    European Journal of Cancer, Vol. 148, pp. 382-394

2019

  1. Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study

    Clinical Breast Cancer, Vol. 19, Núm. 2, pp. 105-112

  2. Survival impact of primary tumor resection in de novo metastatic breast cancer patients (GEICAM/El Alamo Registry)

    Scientific Reports, Vol. 9, Núm. 1

2016

  1. Incidence of chemotherapy-induced nausea and vomiting associated with docetaxel and cyclophosphamide in early breast cancer patients and aprepitant efficacy as salvage therapy. Results from the Spanish Breast Cancer Group/2009-02 study

    European Journal of Cancer, Vol. 58, pp. 122-129

2011

  1. Phase I/II study of biweekly vinorelbine and oxaliplatin as first-line treatment in patients with metastatic breast cancer

    Anti-Cancer Drugs, Vol. 22, Núm. 3, pp. 283-289

2010

  1. Current controversies in the management of breast cancer

    Clinical and Translational Oncology, Vol. 12, Núm. 4, pp. 278-286

  2. Erratum: Current controversies in the management of breast cancer (Clinical and Translational Oncology 12:4 (278-286))

    Clinical and Translational Oncology

2008

  1. A single-nucleotide polymorphismin the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma

    Clinical Cancer Research, Vol. 14, Núm. 3, pp. 811-816

  2. Neoadjuvant endocrine therapy for breast cancer: Past, present and future

    Anti-Cancer Drugs, Vol. 19, Núm. 4, pp. 339-347

  3. Time-to-progression in breast cancer: A stratification model for clinical trials

    Breast, Vol. 17, Núm. 3, pp. 239-244

2001

  1. Circulating angiogenic growth factors as predictive factors in metastatic breast cancer treated with letrozole

    Breast Cancer Research and Treatment, Vol. 69, Núm. 3, pp. 244

  2. Serum HER-2 ECD and the efficacy of letrozole in ER+/ PR+ metastatic breast cancer: Preliminary results of a prospective study

    Breast Cancer Research and Treatment, Vol. 69, Núm. 3, pp. 242